BPMC Blueprint Medicines
- 89.540
- +1.190+1.35%
- 89.540
- 0.0000.00%
Blueprint Medicines所有资讯
Blueprint Medicines | 4：持股变动声明-高管 Rossi Christina
Blueprint Medicines | 4：持股变动声明-董事 Albers Jeffrey W.
Blueprint Medicines | 144：拟议出售证券
Blueprint Medicines | 8-K：重大事件
Blueprint Medicines | 4：持股变动声明-高管 Hurley Ariel
Blueprint Medicines | 144：拟议出售证券
Blueprint Medicines | 4：持股变动声明-高管 Haviland Kate
Blueprint Medicines | 4：持股变动声明-高管 Rossi Christina
Blueprint Medicines | 144：拟议出售证券
Blueprint Medicines | 144：拟议出售证券
Blueprint Medicines | 4：持股变动声明-董事 COATS LONNEL
Blueprint Medicines | 144：拟议出售证券
Blueprint Medicines | 144：拟议出售证券
Blueprint Medicines | SC 13G/A：超过5%持股股东披露文件(修正)-T. ROWE PRICE ASSOCIATES, INC.(8.5%)
Blueprint Medicines | 4：持股变动声明-董事 Albers Jeffrey W.
Blueprint Medicines | 144/A：其他
Blueprint Medicines | 144：拟议出售证券
Blueprint Medicines | 10-Q：2024财年三季报
Blueprint Medicines | 8-K：Blueprint Medicinib 公布2024年第三季度业绩并上调了AYVAKIT® /AyvaKYT®（avapritinib）全年收入指引
Blueprint Medicines | 4：持股变动声明-高管 Namouni Fouad
暂无数据
